(1R,2S,4S,5S)-PHOPHORIC-ACID-MONO-[4-(2-CHLORO-6-METHYLAMINO-PURIN-9-YL)-1-HYDROXYMETHYL-BICYCLO-[3.1.0]-HEX-2-YL]-ESTER
Compound with spectra: 1 NMR
![(1R,2S,4S,5S)-PHOPHORIC-ACID-MONO-[4-(2-CHLORO-6-METHYLAMINO-PURIN-9-YL)-1-HYDROXYMETHYL-BICYCLO-[3.1.0]-HEX-2-YL]-ESTER](/api/compound/7o2pdu19AxB.png?ph=true&h=300&w=458 "(1R,2S,4S,5S)-PHOPHORIC-ACID-MONO-[4-(2-CHLORO-6-METHYLAMINO-PURIN-9-YL)-1-HYDROXYMETHYL-BICYCLO-[3.1.0]-HEX-2-YL]-ESTER")
| SpectraBase Compound ID | 7o2pdu19AxB |
|---|---|
| InChI | InChI=1S/C13H17ClN5O5P/c1-15-10-9-11(18-12(14)17-10)19(5-16-9)7-2-8(24-25(21,22)23)13(4-20)3-6(7)13/h5-8,20H,2-4H2,1H3,(H,15,17,18)(H2,21,22,23)/t6-,7+,8+,13-/m1/s1 |
| InChIKey | JBPZNHLPOYFQSQ-QRMHULIRSA-N |
| Mol Weight | 389.74 g/mol |
| Molecular Formula | C13H17ClN5O5P |
| Exact Mass | 389.065583 g/mol |
| Enantiomer InChIKey | JBPZNHLPOYFQSQ-PSWSROFUSA-N |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | D2O |
(1'S,2'R,3'S,4'R,5'S)-4-(6-AMINO-9H-PURIN-9-YL)-1-[PHOSPHORYLOXYMETHYL]-BICYCLO-[3.1.0]-HEXANE-2,3-DIOL
(1'-S,2'-R,3'-S,4'-R,5'-S)-4'-(6-AMINOPURIN-9-YL)-2',3'-(DIHYDROXY)-1'-(PHOSPHONOETHENYL)-BICYCLO-[3.1.0]-HEXANE
2'-Deoxy-8,2'-methylene-cycloadenosine
glutaric acid [4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl ester [4-[(E)-2-nitrovinyl]phenyl] ester
2',3'-O-ISOPROPYLIDENEADENOSINE-5'-(4-[(E)-2-NITROETHENYL]-PHENYL-GLUTARATE
2',3'-O-ISOPROPYLIDENE-5-DEOXY-5-METHYLTHIO-5-FLUOROADENOSINE(DIASTEREOMER 1)
(1'-S,2'-R,3'-S,4'-R,5'-S)-4'-(6-AMINOPURIN-9-YL)-2',3'-(DIHYDROXY)-1'-(PHOSPHONOMETHYLENE)-BICYCLO-[3.1.0]-HEXANE
(1'-S,2'-R,3'-S,4'-R,5'-S)-4'-(6-AMINOPURIN-9-YL)-2',3'-(DIHYDROXY)-1'-[(E)-PHOSPHONOETHENYL]-BICYCLO-[3.1.0]-HEXANE
2',3'-O-isopropylidene-N(6)-methyl-N(6)-formyl-adenosine
(2R,3R,4R,5R)-2-(6-((E)-4-acetoxy-3-methylbut-2-enylamino)-9H-purin-9-yl)-5-(acetoxymethyl)tetrahydrofuran-3,4-diyl diacetate
| Title | Journal or Book | Year |
|---|---|---|
| Acyclic Analogues of Adenosine Bisphosphates as P2Y Receptor Antagonists: Phosphate Substitution Leads to Multiple Pathways of Inhibition of Platelet Aggregation | Journal of Medicinal Chemistry | 2002 |